Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT) has awarded equity incentives to 8 new employees hired in December 2024. The company granted a total of 10,660 restricted stock units (RSUs) as employment inducement awards. These RSUs will vest over four years, with 25% vesting annually on each anniversary of the December 31, 2024 grant date. The equity awards were approved by the Compensation Committee under Sarepta's 2024 Employment Commencement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Sarepta Therapeutics (NASDAQ:SRPT) ha assegnato incentivi azionari a 8 nuovi dipendenti assunti a dicembre 2024. L'azienda ha concesso un totale di 10.660 unità azionarie vincolate (RSU) come premi per l'assunzione. Queste RSU saranno maturate nel corso di quattro anni, con il 25% che si matura annualmente in occasione di ogni anniversario della data di concessione del 31 dicembre 2024. I premi azionari sono stati approvati dal Comitato per le Compensazioni nell'ambito del Piano di Incentivi per l'Inizio dell'Occupazione del 2024 di Sarepta e sono conformi alla Regola di quotazione Nasdaq 5635(c)(4).
Sarepta Therapeutics (NASDAQ:SRPT) ha otorgado incentivos de acciones a 8 nuevos empleados contratados en diciembre de 2024. La empresa concedió un total de 10,660 unidades de acciones restringidas (RSUs) como premios de inducimiento laboral. Estas RSUs se consolidarán durante cuatro años, con el 25% consolidándose anualmente en cada aniversario de la fecha de concesión del 31 de diciembre de 2024. Los premios de acciones fueron aprobados por el Comité de Compensación bajo el Plan de Incentivos para el Inicio de Empleo de 2024 de Sarepta y cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq.
사레프타 테라퓨틱스(SAREPTA THERAPEUTICS) (NASDAQ:SRPT)는 2024년 12월에 채용된 8명의 신입 직원에게 주식 인센티브를 지급했습니다. 회사는 10,660개의 제한 주식 단위(RSU)를 고용 유도 보상으로 지급했습니다. 이 RSU는 4년 동안 분할 지급되며, 2024년 12월 31일 부여일의 매년 기념일에 25%가 지급됩니다. 주식 보상은 사레프타의 2024년 고용 시작 인센티브 계획에 따라 보상 위원회에서 승인되었으며, 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
Sarepta Therapeutics (NASDAQ:SRPT) a attribué des incitations en actions à 8 nouveaux employés recrutés en décembre 2024. L'entreprise a accordé un total de 10 660 unités d'actions restreintes (RSU) en tant que primes d'incitation à l'emploi. Ces RSU seront acquises sur une période de quatre ans, avec 25 % acquises chaque année à l'anniversaire de la date d'attribution du 31 décembre 2024. Les attributions d'actions ont été approuvées par le Comité de Rémunération dans le cadre du Plan d’Incitation au Début de l’Emploi 2024 de Sarepta et sont conformes à la règle de cotation Nasdaq 5635(c)(4).
Sarepta Therapeutics (NASDAQ:SRPT) hat 8 neuen Mitarbeitern, die im Dezember 2024 eingestellt wurden, Aktienanreize gewährt. Das Unternehmen hat insgesamt 10.660 beschränkte Aktieneinheiten (RSUs) als Einstellungsanreiz vergeben. Diese RSUs werden über vier Jahre hinweg ervestet, wobei jährlich 25% am Jahrestag des Gewährungsdatums am 31. Dezember 2024 fällig werden. Die Aktienvergaben wurden vom Vergütungsausschuss im Rahmen des 2024 Einstellungsbeginn-Anreizplans von Sarepta genehmigt und entsprechen der Nasdaq-Notierungsregel 5635(c)(4).
- Successful attraction of new talent with 8 new hires
- Implementation of structured employee retention program through 4-year vesting RSUs
- None.
The employees received in the aggregate 10,660 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241231089707/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many RSUs did Sarepta Therapeutics (SRPT) grant in December 2024?
What is the vesting schedule for SRPT's December 2024 RSU grants?
Did SRPT include stock options in their December 2024 inducement grants?
Under which plan were SRPT's December 2024 inducement grants approved?
